Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 1051 for “"triple-negative"”.
-
Triple negative breast cancer-An Overview
Ο τριπλά αρνητικός καρκίνος του μαστού χαρακτηρίζεται από αρνητικούς υποδοχείς οιστρογόνων (ER), αρνητικούς υποδοχείς προγεστερόνης (PR) και αρνητικούς υποδοχείς HER2. Αποτελεί μια ετερογενή ομάδα, και τα χαρακτηριστικά αυτά συνολικά ανευρίσκονται σε 15-20% των περιπτώσεων καρκίνου του μαστού. O …
-
The Biology of Triple Negative Breast Cancer
… of cancer-related mortality. Among its subtypes, triple-negative breast cancer (TNBC) is the most aggressive, accounting for 15–20% of all breast cancer cases. TNBC is defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Due to the lack of targeted …
-
CircREV1 Expression in Triple-Negative Breast Cancer
Triple-negative breast cancer (TNBC) comprises only 24% of breast cancer cases, yet is the second leading cause of cancer mortality in women due to its aggressive nature (1). This increase in mortality is due to the lack of receptors for three targetable growth factors (HER2, progesterone, and …
-
MESOTHELIN EXPRESSION AND TRIPLE-NEGATIVE BREAST CANCER
… biomarker, is more often overexpressed in triple receptor-negative breast cancer (TNBC) than in common luminal breast tumor subtype or normal tissues. The objective of this systematic review is to determine the association between the expressions of mesothelin with survival outcomes in …
-
Characterising pathways driving aggressive biology and chemoresistance in triple negative breast cancers biology and chemoresistance in triple negative breast cancers
This body of work served to investigate the mechanisms driving chemoresistance in a series of in vitro TNBC cell line models. Molecular characterisation and comparison of drug resistant models allowed for the identification of promising druggable targets, whose efficacy in restoring …
-
Advancing Triple-Negative Breast Cancer Therapies with Mebendazole
… of all breast cancer is the highly invasive triple negative breast cancer (TNBC) which lacks estrogen, progesterone, and ERBB2 receptors. TNBC is difficult to treat due to its aggressive nature which includes fast growth rate and ability to metastasize. Current treatments for patients with TN …
-
c-Met/HGF in triple negative breast cancer
Triple negative breast cancer (TNBC) is a subtype of breast cancer which is negative for the oestrogen receptor, progesterone receptor and lacks over-expression of HER2. The aim of this PhD was to examine c-Met and its ligand HGF as potential targets for TNBC. Expression of c-Met was higher in TNBC …
-
Mineralocorticoid receptor signaling in Triple-negative Breast Cancer
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that lacks expression of hormone receptors and HER2 (Human epidermal growth factor 2) receptor overexpression. Even in the face of initially effective treatments, TNBC patients relapse and develop therapy resistance. One …
-
Targeted Combination Therapy Of Triple-Negative Breast Cancer
TARGETED COMBINATION THERAPY OF TRIPLE-NEGATIVE BREAST CANCERby KETKI BHISE May 2021 Advisor: Dr. Arun Iyer Major: Pharmaceutical Sciences Degree: Doctor of Philosophy Triple Negative Breast Cancer (TNBC) accounts for 10-20% of the total breast carcinoma cases. There is no FDA-approved targeted …
-
Tyrosine Kinase Inhibitors in Triple Negative Breast Cancer
Basal-like breast cancers are generally negative for estrogen and progesterone receptor expression and HER-2 amplification (‘triple negative’ breast cancer, TNBC), and express basal cytokeratins 5/6, and EGFR (epidermal growth factor receptor). No targeted therapy options are currently approved for …
-
Mechanism of metastasis of triple negative breast cancer
Triple Negative Breast Cancer (TNBC) is increasingly recognised as a serious, worldwide public health concern. TNBC has the ability to recur after treatment and appears to be greatest in the first few years. The phenotypical changes of the TNBC metastasis represent a unique that heterogeneous …
-
NEW THERAPIES FOR CREB3L1-DEFICIENT TRIPLE NEGATIVE BREAST CANCER
ABSTRACT The lack of targeted therapies for triple-negative breast cancer (TNBC) contributes to their high mortality rates and high risk of relapse compared to other subtypes of breast cancer. Developing targeted therapies for TNBC is an unmet clinical need. Our lab has described metastasis …
-
Genetic Analysis of Triple-Negative Breast Cancer and Pineoblastoma
Metastatic triple-negative breast cancer (TNBC) is a devastating disease affecting relatively young women. The tumor suppressor genes TP53 and RB1 are commonly lost together in a subset of TNBC with exceedingly poor prognosis. The identification of oncogenic drivers that cooperate with p53/Rb-loss …
-
Targeting EGFR signalling pathway in triple negative breast cancer
… is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic responses of TNBC to the EGFR-targeted therapy, …
-
Targeting EGFR signalling pathway in triple negative breast cancer
… is frequently overexpressed in the majority of triple negative breast cancer patients (TNBC). However, the molecular determinants behind their limited response to EGFR-targeted therapies are poorly understood. Here, both the acute and chronic responses of TNBC to the EGFR-targeted therapy, …
-
Adaptation to chronic hypoxia in triple-negative breast cancer
… in its association with poor prognosis. Triple-negative breast cancer has the worst prognosis of all breast cancer subtypes with a 5 year survival rate of only 76.7%, and only 10.8% if the cancer has already metastasised. In line with this, triple-negative tumours often have higher levels …
-
Platinum nanoparticles, targeted therapy for triple negative breast cancer
… Hence, in this work, a new treatment option for triple negative breast cancer (TNBC) based on Pt NPs is developed. TNBC is a type of breast cancer that lacks the three common receptors used for immunotherapy and with a tendency to metastasize faster. Consequently, TNBC has a worst prognosis and …
-
Drug-loaded magnetoliposomes for triple negative breast cancer therapy
A nanotecnologia surgiu como uma área fundamental para o desenvolvimento e manipulação de materiais à escala nanométrica, com diversas aplicações, especialmente nas ciências biomédicas. As nanopartículas (NPs) magnéticas podem ser encapsuladas em lipossomas ou revestidas com bicamadas lipídicas, …
-
Regulation of Phenotypic Plasticity in Triple-Negative Breast Cancer
… with a basal-like gene signature are primarily triple-negative, are frequently metastatic, and carry the worst prognosis. Basal-like breast cancers are frequently enriched for markers of breast cancer stem cells as well as markers of epithelial-mesenchymal transition (EMT). While EMT is …
Page 1 of 53